Aquestive Therapeutics (AQST) Change in Cash (2017 - 2026)

Aquestive Therapeutics' Change in Cash history runs 10 years deep, the most recent figure standing at -$10.4 million for Q1 2026.

• In Q1 2026, Change in Cash fell 261.2% year-over-year to -$10.4 million; the TTM figure through Mar 2026 stood at $42.1 million (up 258.52% YoY), while the FY2025 annual figure was $49.6 million, up 4.09% from the prior year.
• Change in Cash was -$10.4 million for Q1 2026 at Aquestive Therapeutics, down from -$7.9 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $71.3 million in Q1 2024 to a low of -$13.3 million in Q1 2022.
• Historically, Change in Cash has averaged $4.9 million across 5 years, with a median of -$2.9 million in 2025.
• Biggest YoY gain for Change in Cash was 18342.46% in 2024; the steepest drop was 582.75% in 2024.
• A 5-year view of Change in Cash shows it stood at $8.6 million in 2022, then sank by 112.12% to -$1.0 million in 2023, then slumped by 507.37% to -$6.3 million in 2024, then fell by 24.37% to -$7.9 million in 2025, then sank by 32.19% to -$10.4 million in 2026.
• The last three Change in Cash figures came in at -$10.4 million (Q1 2026), -$7.9 million (Q4 2025), and $68.5 million (Q3 2025), per Business Quant data.